Takashi Kobunai
Overview
Explore the profile of Takashi Kobunai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
618
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wakasa T, Nonaka K, Harada A, Ohkawa Y, Kikutake C, Suyama M, et al.
Cell Death Discov
. 2024 Jul;
10(1):307.
PMID: 38956056
The fluorinated thymidine analog trifluridine (FTD) is a chemotherapeutic drug commonly used to treat cancer; however, the mechanism by which FTD induces cytotoxicity is not fully understood. In addition, the...
2.
Tanaka T, Kobunai T, Yamamoto Y, Murono K, Emoto S, Hiyoshi M, et al.
Anticancer Res
. 2020 Jan;
40(1):101-107.
PMID: 31892558
Background: Mitochondria are energy-producing organelles, and dysfunction in these organelles causes various types of disease. Although several studies have identified mutations in nuclear DNA that are associated with the etiology...
3.
Tsunekuni K, Konno M, Haraguchi N, Koseki J, Asai A, Matsuoka K, et al.
Sci Rep
. 2019 Oct;
9(1):14861.
PMID: 31619711
Cancer stem cells (CSCs) are involved in metastatic colorectal cancer recurrence, but no effective therapy targeting these cells is currently available. Because trifluridine (FTD)/tipiracil therapy is used for refractory colorectal...
4.
Kobunai T, Matsuoka K, Takechi T
Anticancer Res
. 2019 Jul;
39(7):3565-3570.
PMID: 31262880
Background/aim: Trifluridine (FTD) is a key component of the novel oral antitumor drug trifluridine/tipiracil that has been approved for the treatment of metastatic colorectal cancer. In this study, a comprehensive...
5.
Edahiro K, Iimori M, Kobunai T, Morikawa-Ichinose T, Miura D, Kataoka Y, et al.
Mol Cancer Res
. 2018 Jun;
16(10):1483-1490.
PMID: 29866926
Acquired resistance to therapeutic drugs is a serious problem for patients with cancer receiving systemic treatment. Experimentally, drug resistance is established in cell lines by repeated, continuous exposure to escalating...
6.
Matsuoka K, Nakagawa F, Kobunai T, Takechi T
Oncotarget
. 2018 Mar;
9(17):13438-13450.
PMID: 29568368
Trifluridine/tipiracil (FTD/TPI or TFTD, also known as TAS-102) is a combination of the antineoplastic thymidine analog, FTD, and thymidine phosphorylase inhibitor, TPI (molar ratio 1:0.5). FTD/TPI was approved in Japan,...
7.
Suzuki N, Tsukihara H, Nakagawa F, Kobunai T, Takechi T
Am J Cancer Res
. 2017 Nov;
7(10):2032-2040.
PMID: 29119052
Trifluridine/tipiracil (FTD/TPI) is a combination of FTD, an antineoplastic thymidine-based nucleoside analog, and TPI, which acts to enhance the bioavailability of FTD . It is used to treat patients with...
8.
Matsuoka K, Kobunai T, Nukatsuka M, Takechi T
Biochem Biophys Res Commun
. 2017 Oct;
494(1-2):249-255.
PMID: 29024630
We aimed to assess the combined effect of trifluridine (FTD) and ionizing radiation (IR) on colorectal cancer cells in vitro. Colorectal cancer cells, HT-29, HCT-15, and HCT 116, showing low,...
9.
Tsunekuni K, Konno M, Asai A, Koseki J, Kobunai T, Takechi T, et al.
Oncotarget
. 2017 Sep;
8(32):53017-53027.
PMID: 28881790
Trifluridine (FTD) is a key component of the novel oral antitumor drug trifluridine/tipiracil, which is approved for the treatment of patients with metastatic colorectal cancer refractory to standard chemotherapies. A...
10.
Tanaka T, Kobunai T, Yamamoto Y, Emoto S, Murono K, Kaneko M, et al.
Cancer Genomics Proteomics
. 2017 Sep;
14(5):341-348.
PMID: 28871001
Background: Patients with ulcerative colitis (UC) are at risk of UC-associated colorectal cancer (CRC); however, little is known about genetic alterations occurring during UC carcinogenesis. We examined mutational changes in...